ACCESS INITIATIVE

The American Society for Transplantation and Cellular Therapy (ASTCT) and NMDP formed the ACCESS Initiative to address access and outcome disparities in the hematopoietic cell transplantation (HCT) and cell therapy (CT) ecosystem.

Read about the ACCESS Initiative's founding, efforts and goals in this open-access article from ASTCT's journal, *Transplantation and Cellular Therapy*.

Purpose: To reduce barriers to hematopoietic cell therapy and transplantation through implementation of changes in practice and policy by active, sustained engagement of the cell therapy ecosystem

Vision: To advance, measure and sustain progress toward universal access in the initial focus areas of awareness, poverty and racial inequality

Leadership and Committees: Co-Chairs – Jeffery Auletta, MD and Stella M. Davies, MBBS, PhD, MRC head up the initiative supported by co-chairs of these committees: Poverty, Racial/Ethnic Inequity, and Awareness. Learn more about each committee and their work here.

GET INVOLVED

Interested in supporting the ACCESS Initiative? Click on the QR to fill out a brief survey to express your interest.

News and Opportunities

Are you attending ASCO or SOHO annual conferences? Your expertise is needed!
The Awareness Committee is in early planning stages of putting together an in-person MDS-themed roundtable at the upcoming ASCO and SOHO annual conferences Your expertise and insights would be invaluable to our discussion. If you're planning to attend either conference and are open to participating as a panelist (all ACCESS Initiative members are welcome), kindly reach out to Anna Cincotta at acincott@nmdp.org as soon as possible. Anna will provide further details and address any queries you may have.

ACCESS Initiative Making a Difference

The 2023 National Alliance for Caregiving report on *Transplant Caregiving in the U.S: A Call for System Change* references the ACCESS Initiative project, *Assessing Medicaid Coverage for hematopoietic cell transplantation and chimeric antigen receptor t cell therapy*. Read the report here.